The effectiveness of nano-curcumin on patients with COVID-19: A systematic review of clinical trials
The effectiveness of nano-curcumin on patients with COVID-19: A systematic review of clinical trials
Shojaei et al., 2023 | Phytother Res | Systematic Review
Citation
Shojaei Mehrnaz, Foshati Sahar, ... Sahebkar Amirhossein. The effectiveness of nano-curcumin on patients with COVID-19: A systematic review of clinical trials. Phytother Res. 2023-Apr;37(4):1663-1677. doi:10.1002/ptr.7778
Abstract
The main aim of the current study was to summarize the findings of available clinical studies to assess nano-curcumin's influence on COVID patients. A comprehensive online search was performed in Scopus, PubMed, ISI Web of Science, and Google Scholar until March 2022 to identify trials that investigated the effects of nano-curcumin in patients with COVID-19. Eight studies comprising 569 patients were included in this review. Compared with placebo, nano-curcumin had no significant effect on C-reactive protein (CRP) and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). However, gene expression of IL-6 and gene expression as well as secretion of interleukin-1 beta (IL-1β) significantly decreased following nano-curcumin intervention. Nano-curcumin had beneficial effects on fever, cough, chills, myalgia, and olfactory and taste disturbances. The duration of hospitalization and mortality rate were significantly lower in the nano-curcumin group compared with the control group. Lymphocyte count was significantly increased after curcumin supplementation. Nano-curcumin also had favorable effects on O2 saturation, sputum, chest pain, wheeze, and dyspnea in patients with COVID-19. No major adverse effects were reported in response to nano-curcumin supplementation. In summary, the results of this systematic review of clinical trials suggested that nano-curcumin supplementation has beneficial effects on inflammation, respiratory function, disease manifestations, and complications in patients with COVID-19 viral infection.
Key Findings
In summary, the results of this systematic review of clinical trials suggested that nano-curcumin supplementation has beneficial effects on inflammation, respiratory function, disease manifestations, and complications in patients with COVID-19 viral infection.
Outcomes Measured
- C-reactive protein
Population
| Field | Value |
|---|---|
| Population | covid |
| Sample Size | 569 |
| Age Range | See abstract |
| Condition | inflammation |
MeSH Terms
- Humans
- COVID-19
- Curcumin
- Interleukin-6
- C-Reactive Protein
- Inflammation
Evidence Classification
- Level: Systematic Review
- Publication Types: Systematic Review, Journal Article
- Vertical: curcumin
Provenance
- PMID: 36799442
- DOI: 10.1002/ptr.7778
- PMCID: Not in PMC
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09